Compounds and methods for treating insulin resistance syndrome
OwnerStephen Michael Cohen, Wei Zhanginventors
Life of this patent
Estimating the term…
Abstract
The present invention relates to a method of treating or preventing insulin resistance syndrome in an animal body by administering an inhibitor of protein kinase RNA-like endoplasmic reticulum kinase (PERK) gene, or a functional variant thereof, or an inhibitor of PERK protein or a functional variant thereof or a method of reducing activity of transcription factors of the FOXO family (Foxo 1, 3a, 4 and 6) by administering an inhibitor of protein kinase RNA-like endoplasmic reticulum kinase (PERK) gene, or a functional variant thereof, or an inhibitor of PERK protein or a functional variant thereof. The present invention also relates to different compounds and methods for using PERK gene or PERK protein.
Claims41
A method of treating or preventing insulin resistance syndrome in an animal body by administering an inhibitor of protein kinase RNA-like endoplasmic reticulum kinase (PERK) gene, or a functional variant thereof, or an inhibitor of PERK protein or a functional variant thereof.
A method of reducing activity of transcription factors of the FOXO family (Foxo1, 3a, 4 and 6) by administering an inhibitor of protein kinase RNA-like endoplasmic reticulum kinase (PERK) gene, or a functional variant thereof, or an inhibitor of PERK protein or a functional variant thereof.
(canceled)
(canceled)
(canceled)
(canceled)
siRNA directed against the nucleic acid transcribed from the PERK gene.
An antibody, or a functional variant thereof, or a fragment of the antibody capable of binding to PERK protein.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A pharmaceutical composition comprising an inhibitor of PERK gene or a functional variant thereof, or an inhibitor of PERK protein or a functional variant thereof.
(canceled)
A method of identifying a compound that modulates expression of PERK gene in a cell, the method comprising:
- a. exposing cells expressing the PERK gene with a test compound;
- b. determining the expression level of the PERK gene in the cells which were exposed to the test compound under (a);
- c. comparing the level of expression of the PERK gene determined under (b) with the expression of the PERK gene in control cells which were not exposed to the test compound;
- wherein a difference in the expression level between the cells under (b) compared to the control cells identifies the compound that modulates expression of the PERK gene in a cell.
A method of identifying a compound that modulates the amount or activity of PERK protein comprised in a cell, the method comprising:
- a. exposing cells expressing PERK protein with a test compound;
- b. determining the amount or activity of PERK protein in the cells which were exposed to the test compound under (a);
- c. comparing the amount or activity of PERK protein determined under (b) with the activity of PERK protein in control cells not exposed to the test compound;
- wherein a difference in the amount or activity of PERK protein between the cells under (b) compared to the control cells identifies the compound that modulates the amount of PERK protein in the cells.
A method of identifying a compound that modulates the amount of PERK protein comprised in a cell, the method comprising:
- a. exposing cells expressing PERK protein with a test compound;
- b. determining the amount of PERK protein in the cells which were exposed to the test compound under (a);
- c. comparing the amount of PERK protein determined under (b) with the amount of PERK in control cells not exposed to the test compound;
- wherein a difference in the amount of PERK protein between the cells under (b) compared to the control cells identifies the compound that modulates the amount of PERK protein in the cells.
A prognostic method for determining the receptiveness of a patient suffering from insulin resistance syndrome for a treatment with a PERK inhibitor, wherein the method comprises identifying and determining the PERK activity in the patient, wherein an increased PERK activity indicates that the person may be receptive for a treatment with a PERK inhibitor.
(canceled)
A prognostic method for determining the receptiveness of a patient suffering from insulin resistance syndrome for a treatment with a PERK inhibitor, wherein the method comprises measuring activity of a protein kinase AKT and/or PI3Kinase activity in a subject, wherein in comparison to a control a lowered AKT activity and/or lowered PI3Kinase activity indicates that the patient may be receptive for a treatment with a PERK inhibitor.
(canceled)
A prognostic method for determining the receptiveness of a patient suffering from insulin resistance syndrome for a treatment with a PERK inhibitor, wherein the method comprises measuring the relative levels of phosphorylation on the AKT site and on the PERK site(s), wherein a lower ratio of AKT site phosphorylation to PERK site phosphorylation indicates that the patient is receptive for a treatment with a PERK inhibitor.
(canceled)
A kit for use in treating or preventing insulin resistance syndrome in a patient, said kit comprises one of the following selected from the group consisting of a siRNA directed against the nucleic acid transcribed from the PERK gene, an antibody, or a functional variant thereof, or a fragment of the antibody capable of binding to PERK protein and a pharmaceutical composition comprising an inhibitor of PERK gene or a functional variant thereof, or an inhibitor of PERK protein or a functional variant thereof.
A kit for determining whether a patient suffering from insulin resistance syndrome is receptive for a treatment with a PERK inhibitor, wherein the kit comprises:
- a. antibodies specific to one or more of the AKT phosphorylation site(s) on one or more of the human FOXO proteins;
- and
- b. antibodies specific for one or more of the PERK phosphorylation site(s) on one or more of the human FOXO proteins or for one or more of the PERK phosphorylation site(s) on PERK protein or on elF2α.
(canceled)
(canceled)
Dependencies are inferred from the claim text.